Vanda Pharmaceuticals Inc - Asset Resilience Ratio
Vanda Pharmaceuticals Inc (VNDA) has an Asset Resilience Ratio of 36.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vanda Pharmaceuticals Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Vanda Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Vanda Pharmaceuticals Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Vanda Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Vanda Pharmaceuticals Inc (VNDA) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $179.00 Million | 36.61% |
| Total Liquid Assets | $179.00 Million | 36.61% |
Asset Resilience Insights
- Very High Liquidity: Vanda Pharmaceuticals Inc maintains exceptional liquid asset reserves at 36.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vanda Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Vanda Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Vanda Pharmaceuticals Inc (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Vanda Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 36.61% | $179.00 Million | $488.95 Million | -4.89pp |
| 2024-12-31 | 41.50% | $272.33 Million | $656.20 Million | +2.57pp |
| 2023-12-31 | 38.93% | $252.44 Million | $648.44 Million | -13.39pp |
| 2022-12-31 | 52.32% | $331.83 Million | $634.25 Million | -11.80pp |
| 2021-12-31 | 64.12% | $380.74 Million | $593.79 Million | +6.63pp |
| 2020-12-31 | 57.49% | $306.71 Million | $533.46 Million | +2.29pp |
| 2019-12-31 | 55.21% | $267.06 Million | $483.75 Million | -3.91pp |
| 2018-12-31 | 59.12% | $196.35 Million | $332.13 Million | +5.68pp |
| 2017-12-31 | 53.44% | $109.79 Million | $205.43 Million | +5.47pp |
| 2016-12-31 | 47.97% | $100.91 Million | $210.37 Million | +4.63pp |
| 2015-12-31 | 43.34% | $92.34 Million | $213.05 Million | +3.20pp |
| 2014-12-31 | 40.14% | $68.92 Million | $171.70 Million | -5.61pp |
| 2013-12-31 | 45.75% | $65.59 Million | $143.35 Million | +22.40pp |
| 2012-12-31 | 23.35% | $31.63 Million | $135.45 Million | -10.03pp |
| 2011-12-31 | 33.38% | $60.96 Million | $182.62 Million | -39.58pp |
| 2010-12-31 | 72.96% | $155.48 Million | $213.10 Million | +58.18pp |
| 2008-12-31 | 14.78% | $7.38 Million | $49.93 Million | -29.87pp |
| 2007-12-31 | 44.65% | $43.24 Million | $96.86 Million | +42.05pp |
| 2006-12-31 | 2.60% | $941.98K | $36.26 Million | -25.77pp |
| 2005-12-31 | 28.36% | $10.14 Million | $35.75 Million | -- |
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more